Last reviewed · How we verify
Ceftolozane-tazobactam + Meropenem
This combination inhibits bacterial cell wall synthesis through dual beta-lactam action (ceftolozane-tazobactam and meropenem) while tazobactam protects against beta-lactamase resistance.
This combination inhibits bacterial cell wall synthesis through dual beta-lactam action (ceftolozane-tazobactam and meropenem) while tazobactam protects against beta-lactamase resistance. Used for Complicated intra-abdominal infections, Hospital-acquired and ventilator-associated bacterial pneumonia, Complicated urinary tract infections.
At a glance
| Generic name | Ceftolozane-tazobactam + Meropenem |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Beta-lactam antibiotic combination |
| Target | Bacterial penicillin-binding proteins (PBPs); beta-lactamase inhibition |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftolozane is a fifth-generation cephalosporin with enhanced activity against Pseudomonas aeruginosa and gram-negative bacteria, while tazobactam is a beta-lactamase inhibitor that prevents enzymatic degradation of the beta-lactams. Meropenem is a broad-spectrum carbapenem that provides additional coverage against resistant gram-negative and gram-positive organisms. Together, this triple combination targets multiple resistance mechanisms and provides synergistic antimicrobial activity.
Approved indications
- Complicated intra-abdominal infections
- Hospital-acquired and ventilator-associated bacterial pneumonia
- Complicated urinary tract infections
- Multi-drug resistant gram-negative infections
Common side effects
- Diarrhea
- Nausea
- Headache
- Phlebitis at infusion site
- Seizures (rare, carbapenem-associated)
Key clinical trials
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens (PHASE4)
- Nosocomial Infections in ECMO Patients
- Use of New Antibiotics in Sweden
- MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) (PHASE2)
- MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) (PHASE2)
- Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015) (PHASE3)
- Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: